Importer of Controlled Substances Application: Hybrid Pharma, 20696-20697 [2024-06188]
Download as PDF
<![CDATA[
20696
Federal Register / Vol. 89, No. 58 / Monday, March 25, 2024 / Notices
information regarding known historic
properties during the public scoping
period at https://www.boem.gov/
renewable-energy/state-activities/
vineyard-northeast. BOEM’s effects
analysis for historic properties will be
available for public and consulting party
comment with the draft EIS.
6. Information on other current or
planned activities in, or in the vicinity
of, the Project, their possible impacts on
the Project, and the Project’s possible
impacts on those activities.
7. Other information relevant to the
proposed action and its impacts on the
human environment.
To promote informed decisionmaking, comments should be as specific
as possible and should provide as much
detail as necessary to meaningfully and
fully inform BOEM of the commenter’s
position. Comments should explain why
the issues raised are important to the
consideration of potential
environmental impacts and possible
alternatives to the proposed action, as
well as economic, employment, and
other impacts affecting the quality of the
human environment.
The draft EIS will include a summary
of all alternatives, information, and
analyses submitted during the scoping
process for consideration by BOEM and
the cooperating agencies.
(Authority: 42 U.S.C. 4321 et seq., and 40
CFR 1501.9)
[FR Doc. 2024–06161 Filed 3–22–24; 8:45 am]
BILLING CODE 4340–98–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–24–013]
Sunshine Act Meetings
United
States International Trade Commission.
TIME AND DATE: March 29, 2024 at 11
a.m.
PLACE: Room 101, 500 E Street SW,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: none.
2. Minutes.
3. Ratification List.
4. Commission vote on Inv. Nos. 701–
TA–706–709 and 731–TA–1667–1672
(Preliminary) (Melamine from Germany,
India, Japan, Netherlands, Qatar, and
Trinidad and Tobago). The Commission
currently is scheduled to complete and
khammond on DSKJM1Z7X2PROD with NOTICES
VerDate Sep<11>2014
18:08 Mar 22, 2024
Jkt 262001
By order of the Commission.
Issued: March 20, 2024.
Sharon Bellamy,
Supervisory Hearings and Information
Officer.
[FR Doc. 2024–06297 Filed 3–21–24; 11:15 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on February 5, 2024,
Caligor Coghlan Pharma Services, 1500
Business Park Drive, Unit B, Bastrop,
Texas 78602, applied to be registered as
an importer of the following basic
class(es) of controlled substance(s):
Controlled substance
[Docket No. DEA–1340]
Importer of Controlled Substances
Application: Caligor Coghlan Pharma
Services
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Karen Baker,
Chief, Office of Renewable Energy Programs,
Bureau of Ocean Energy Management.
AGENCY HOLDING THE MEETING:
file its determinations on April 1, 2024;
views of the Commission currently are
scheduled to be completed and filed on
April 8, 2024.
5. Outstanding action jackets: none.
CONTACT PERSON FOR MORE INFORMATION:
Sharon Bellamy, Supervisory Hearings
and Information Officer, 202–205–2000.
The Commission is holding the
meeting under the Government in the
Sunshine Act, 5 U.S.C. 552(b). In
accordance with Commission policy,
subject matter listed above, not disposed
of at the scheduled meeting, may be
carried over to the agenda of the
following meeting.
Caligor Coghlan Pharma
Services has applied to be registered as
an importer of basic class(es) of
controlled substance(s). Refer to
SUPPLEMENTARY INFORMATION listed
below for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 24, 2024. Such
persons may also file a written request
for a hearing on the application on or
before April 24, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
SUMMARY:
PO 00000
Frm 00068
Fmt 4703
Sfmt 4703
Psilocyn ...........................
Drug
code
Schedule
I 7438 II
The company plans to import the
listed controlled substance as finished
dosage units for use in clinical trials. No
other activity for this drug code is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–06178 Filed 3–22–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1334]
Importer of Controlled Substances
Application: Hybrid Pharma
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Hybrid Pharma has applied to
be registered as an importer of basic
class(es) of controlled substance(s).
Refer to SUPPLEMENTARY INFORMATION
SUMMARY:
E:\FR\FM\25MRN1.SGM
25MRN1
20697
Federal Register / Vol. 89, No. 58 / Monday, March 25, 2024 / Notices
listed below for further drug
information.
In
accordance with 21 CFR 1301.34(a), this
is notice that on January 22, 2024,
Hybrid Pharma, 1015 West Newport
Center Drive, Suite 106A, Deerfield
Beach, Florida 33442–7707, applied to
be registered as an importer of the
following basic class(es) of controlled
substance(s):
SUPPLEMENTARY INFORMATION:
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before April 24, 2024. Such
persons may also file a written request
for a hearing on the application on or
before April 24, 2024.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
ADDRESSES:
Drug
code
Controlled substance
Dimethyltryptamine ..........
I
7435
Schedule
II
The company plans to import the
listed controlled substance for the
compounding of dosage units to be used
in clinical trials. No other activities for
these drug codes are authorized for this
registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–06188 Filed 3–22–24; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1342]
Bulk Manufacturer of Controlled
Substances Application: Purisys, LLC
Drug Enforcement
Administration, Justice.
AGENCY:
ACTION:
Notice of application.
Purisys, LLC has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to Supplementary
Information listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before May 24, 2024. Such persons
may also file a written request for a
hearing on the application on or before
May 24, 2024.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on February 8, 2024,
Purisys, LLC, 1550 Olympic Drive,
Athens, Georgia 30601–1602, applied to
be registered as a bulk manufacturer of
the following basic class(es) of
controlled substance(s):
SUMMARY:
khammond on DSKJM1Z7X2PROD with NOTICES
Controlled substance
Drug code
Cathinone ...............................................................................................................................................................................
Gamma Hydroxybutyric Acid ..................................................................................................................................................
Ibogaine ..................................................................................................................................................................................
Lysergic acid diethylamide .....................................................................................................................................................
Marihuana Extract ..................................................................................................................................................................
Marihuana ...............................................................................................................................................................................
Tetrahydrocannabinols ...........................................................................................................................................................
Mescaline ...............................................................................................................................................................................
2,5-Dimethoxyamphetamine ...................................................................................................................................................
3,4-Methylenedioxyamphetamine ...........................................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine ..............................................................................................................................
3,4-Methylenedioxymethamphetamine ...................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine ........................................................................................................................................
Diethyltryptamine ....................................................................................................................................................................
Dimethyltryptamine .................................................................................................................................................................
Psilocybin ...............................................................................................................................................................................
Psilocyn ..................................................................................................................................................................................
5-Methyoxy-N,N-diisopropyltryptamine ...................................................................................................................................
Methylone (3,4-Methylenedioxy-N-methylcathinone) .............................................................................................................
Codeine-N-oxide .....................................................................................................................................................................
Dihydromorphine ....................................................................................................................................................................
Heroin .....................................................................................................................................................................................
VerDate Sep<11>2014
18:08 Mar 22, 2024
Jkt 262001
PO 00000
Frm 00069
Fmt 4703
Sfmt 4703
E:\FR\FM\25MRN1.SGM
25MRN1
1235
2010
7260
7315
7350
7360
7370
7381
7396
7400
7404
7405
7431
7434
7435
7437
7438
7439
7540
9053
9145
9200
Schedule
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
]]>Agencies
[Federal Register Volume 89, Number 58 (Monday, March 25, 2024)]
[Notices]
[Pages 20696-20697]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06188]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1334]
Importer of Controlled Substances Application: Hybrid Pharma
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Hybrid Pharma has applied to be registered as an importer of
basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY
INFORMATION
[[Page 20697]]
listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
April 24, 2024. Such persons may also file a written request for a
hearing on the application on or before April 24, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on January 22, 2024, Hybrid Pharma, 1015 West Newport
Center Drive, Suite 106A, Deerfield Beach, Florida 33442-7707, applied
to be registered as an importer of the following basic class(es) of
controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Dimethyltryptamine...................... 7435 I
------------------------------------------------------------------------
The company plans to import the listed controlled substance for the
compounding of dosage units to be used in clinical trials. No other
activities for these drug codes are authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of Food and Drug Administration-approved or non-approved finished
dosage forms for commercial sale.
Marsha Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-06188 Filed 3-22-24; 8:45 am]
BILLING CODE P
